Predictive value of pretreatment metabolic activity measured by fluorodeoxyglucose positron emission tomography in patients with metastatic advanced gastric cancer: The maximal SUV of the stomach is a prognostic factor

Jun Chul Park, Jae Hoon Lee, Kungseok Cheoi, Hyunsoo Chung, Mi Jin Yun, Hyuk Lee, Sung Kwan Shin, Sang Kil Lee, Yong Chan Lee

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Purpose: Few studies have evaluated metabolic activity by 18F-FDG PET as a prognostic factor in advanced gastric cancer (AGC). We investigated its prognostic role in metastatic AGC. Methods: We enrolled 82 patients with metastatic AGC, who were treatment-naive and underwent pretreatment 18F-FDG PET/CT scanning. In each patient, the maximal standardized uptake value (SUVmax) was measured in each target lesion. StomachSUVmax was defined as SUVmax in the stomach, while Total SUVmax was defined as the highest SUVmax among all the target lesions. Results: The stomach was the organ most frequently displaying the highest SUVmax among all the target lesions (in 67.1 % of patients). A TotalSUVmax value of 11.5 was the value with the maximum sum of sensitivity and specificity from receiver-operating characteristic curves for progression-free survival (PFS). PFS was significantly longer in patients with a TotalSUVmax value <11.5 than in those with a Total SUVmax value ≥11.5 (P=0.023); however, overall survival (OS) was not (P=0.055). A StomachSUVmax value of 6.0 was derived by similar methods. PFS and OS were significantly longer in those with a Stomach SUVmax value <6.0 than in those with a StomachSUVmax value ≥6.0 (P=0.001 and P=0.006, respectively). Furthermore, those with a low TotalSUVmax and those with a low StomachSUVmax showed better chemotherapeutic responses (P=0.016 and P=0.034, respectively). Among patients with histologically undifferentiated carcinomas, those with lower TotalSUVmax and those with lower StomachSUVmax showed longer median PFS (P=0.027 and P=0.005, respectively) and OS (P=0.009 and P <0.001, respectively). Multivariate analysis demonstrated Stomach SUVmax as an independent predictor of PFS (P=0.002) and OS (P=0.038). Conclusion: Pretreatment metabolic activity may be a useful prognostic marker in patients with metastatic AGC undergoing palliative chemotherapy. Notably, StomachSUVmax was the single, most robust factor predicting prognosis.

Original languageEnglish
Pages (from-to)1107-1116
Number of pages10
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume39
Issue number7
DOIs
Publication statusPublished - 2012 Jul 1

Fingerprint

Positron-Emission Tomography
Stomach Neoplasms
Stomach
Disease-Free Survival
Survival
Fluorodeoxyglucose F18
ROC Curve
Multivariate Analysis
Carcinoma
Drug Therapy
Sensitivity and Specificity

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging

Cite this

@article{8ce439088297475589d877c62208a879,
title = "Predictive value of pretreatment metabolic activity measured by fluorodeoxyglucose positron emission tomography in patients with metastatic advanced gastric cancer: The maximal SUV of the stomach is a prognostic factor",
abstract = "Purpose: Few studies have evaluated metabolic activity by 18F-FDG PET as a prognostic factor in advanced gastric cancer (AGC). We investigated its prognostic role in metastatic AGC. Methods: We enrolled 82 patients with metastatic AGC, who were treatment-naive and underwent pretreatment 18F-FDG PET/CT scanning. In each patient, the maximal standardized uptake value (SUVmax) was measured in each target lesion. StomachSUVmax was defined as SUVmax in the stomach, while Total SUVmax was defined as the highest SUVmax among all the target lesions. Results: The stomach was the organ most frequently displaying the highest SUVmax among all the target lesions (in 67.1 {\%} of patients). A TotalSUVmax value of 11.5 was the value with the maximum sum of sensitivity and specificity from receiver-operating characteristic curves for progression-free survival (PFS). PFS was significantly longer in patients with a TotalSUVmax value <11.5 than in those with a Total SUVmax value ≥11.5 (P=0.023); however, overall survival (OS) was not (P=0.055). A StomachSUVmax value of 6.0 was derived by similar methods. PFS and OS were significantly longer in those with a Stomach SUVmax value <6.0 than in those with a StomachSUVmax value ≥6.0 (P=0.001 and P=0.006, respectively). Furthermore, those with a low TotalSUVmax and those with a low StomachSUVmax showed better chemotherapeutic responses (P=0.016 and P=0.034, respectively). Among patients with histologically undifferentiated carcinomas, those with lower TotalSUVmax and those with lower StomachSUVmax showed longer median PFS (P=0.027 and P=0.005, respectively) and OS (P=0.009 and P <0.001, respectively). Multivariate analysis demonstrated Stomach SUVmax as an independent predictor of PFS (P=0.002) and OS (P=0.038). Conclusion: Pretreatment metabolic activity may be a useful prognostic marker in patients with metastatic AGC undergoing palliative chemotherapy. Notably, StomachSUVmax was the single, most robust factor predicting prognosis.",
author = "Park, {Jun Chul} and Lee, {Jae Hoon} and Kungseok Cheoi and Hyunsoo Chung and Yun, {Mi Jin} and Hyuk Lee and Shin, {Sung Kwan} and Lee, {Sang Kil} and Lee, {Yong Chan}",
year = "2012",
month = "7",
day = "1",
doi = "10.1007/s00259-012-2116-x",
language = "English",
volume = "39",
pages = "1107--1116",
journal = "European Journal of Nuclear Medicine and Molecular Imaging",
issn = "1619-7070",
publisher = "Springer Verlag",
number = "7",

}

Predictive value of pretreatment metabolic activity measured by fluorodeoxyglucose positron emission tomography in patients with metastatic advanced gastric cancer : The maximal SUV of the stomach is a prognostic factor. / Park, Jun Chul; Lee, Jae Hoon; Cheoi, Kungseok; Chung, Hyunsoo; Yun, Mi Jin; Lee, Hyuk; Shin, Sung Kwan; Lee, Sang Kil; Lee, Yong Chan.

In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 39, No. 7, 01.07.2012, p. 1107-1116.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Predictive value of pretreatment metabolic activity measured by fluorodeoxyglucose positron emission tomography in patients with metastatic advanced gastric cancer

T2 - The maximal SUV of the stomach is a prognostic factor

AU - Park, Jun Chul

AU - Lee, Jae Hoon

AU - Cheoi, Kungseok

AU - Chung, Hyunsoo

AU - Yun, Mi Jin

AU - Lee, Hyuk

AU - Shin, Sung Kwan

AU - Lee, Sang Kil

AU - Lee, Yong Chan

PY - 2012/7/1

Y1 - 2012/7/1

N2 - Purpose: Few studies have evaluated metabolic activity by 18F-FDG PET as a prognostic factor in advanced gastric cancer (AGC). We investigated its prognostic role in metastatic AGC. Methods: We enrolled 82 patients with metastatic AGC, who were treatment-naive and underwent pretreatment 18F-FDG PET/CT scanning. In each patient, the maximal standardized uptake value (SUVmax) was measured in each target lesion. StomachSUVmax was defined as SUVmax in the stomach, while Total SUVmax was defined as the highest SUVmax among all the target lesions. Results: The stomach was the organ most frequently displaying the highest SUVmax among all the target lesions (in 67.1 % of patients). A TotalSUVmax value of 11.5 was the value with the maximum sum of sensitivity and specificity from receiver-operating characteristic curves for progression-free survival (PFS). PFS was significantly longer in patients with a TotalSUVmax value <11.5 than in those with a Total SUVmax value ≥11.5 (P=0.023); however, overall survival (OS) was not (P=0.055). A StomachSUVmax value of 6.0 was derived by similar methods. PFS and OS were significantly longer in those with a Stomach SUVmax value <6.0 than in those with a StomachSUVmax value ≥6.0 (P=0.001 and P=0.006, respectively). Furthermore, those with a low TotalSUVmax and those with a low StomachSUVmax showed better chemotherapeutic responses (P=0.016 and P=0.034, respectively). Among patients with histologically undifferentiated carcinomas, those with lower TotalSUVmax and those with lower StomachSUVmax showed longer median PFS (P=0.027 and P=0.005, respectively) and OS (P=0.009 and P <0.001, respectively). Multivariate analysis demonstrated Stomach SUVmax as an independent predictor of PFS (P=0.002) and OS (P=0.038). Conclusion: Pretreatment metabolic activity may be a useful prognostic marker in patients with metastatic AGC undergoing palliative chemotherapy. Notably, StomachSUVmax was the single, most robust factor predicting prognosis.

AB - Purpose: Few studies have evaluated metabolic activity by 18F-FDG PET as a prognostic factor in advanced gastric cancer (AGC). We investigated its prognostic role in metastatic AGC. Methods: We enrolled 82 patients with metastatic AGC, who were treatment-naive and underwent pretreatment 18F-FDG PET/CT scanning. In each patient, the maximal standardized uptake value (SUVmax) was measured in each target lesion. StomachSUVmax was defined as SUVmax in the stomach, while Total SUVmax was defined as the highest SUVmax among all the target lesions. Results: The stomach was the organ most frequently displaying the highest SUVmax among all the target lesions (in 67.1 % of patients). A TotalSUVmax value of 11.5 was the value with the maximum sum of sensitivity and specificity from receiver-operating characteristic curves for progression-free survival (PFS). PFS was significantly longer in patients with a TotalSUVmax value <11.5 than in those with a Total SUVmax value ≥11.5 (P=0.023); however, overall survival (OS) was not (P=0.055). A StomachSUVmax value of 6.0 was derived by similar methods. PFS and OS were significantly longer in those with a Stomach SUVmax value <6.0 than in those with a StomachSUVmax value ≥6.0 (P=0.001 and P=0.006, respectively). Furthermore, those with a low TotalSUVmax and those with a low StomachSUVmax showed better chemotherapeutic responses (P=0.016 and P=0.034, respectively). Among patients with histologically undifferentiated carcinomas, those with lower TotalSUVmax and those with lower StomachSUVmax showed longer median PFS (P=0.027 and P=0.005, respectively) and OS (P=0.009 and P <0.001, respectively). Multivariate analysis demonstrated Stomach SUVmax as an independent predictor of PFS (P=0.002) and OS (P=0.038). Conclusion: Pretreatment metabolic activity may be a useful prognostic marker in patients with metastatic AGC undergoing palliative chemotherapy. Notably, StomachSUVmax was the single, most robust factor predicting prognosis.

UR - http://www.scopus.com/inward/record.url?scp=84862699614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862699614&partnerID=8YFLogxK

U2 - 10.1007/s00259-012-2116-x

DO - 10.1007/s00259-012-2116-x

M3 - Article

C2 - 22526958

AN - SCOPUS:84862699614

VL - 39

SP - 1107

EP - 1116

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

SN - 1619-7070

IS - 7

ER -